WOODCLIFF LAKE - Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (marketed as HALAVEN) will be presented during the 42nd San Antonio Breast Cancer Symposium (SABCS).
The symposium will be held from December 10-14, 2019, in San Antonio, Texas.
Eisai is presenting a total of five abstracts at this year's SABCS. Presentations of note will include: The results of a post hoc analysis evaluating the relationship between absolute lymphocyte count (ALC) with overall survival (OS) in patients treated with eribulin using data from two Phase 3 studies, EMBRACE and Study 301.
An observational time and motion study of adult females with metastatic breast cancer (MBC) receiving eribulin compared to other treatment options.
A Phase 2 trial evaluating eribulin used in combination with endocrine therapy in the REVERT study, which is currently recruiting patients. Click here for more information.
'We continuously research our medicines to uncover new information that may help the oncology community better understand treatment choices for people living with metastatic breast cancer (MBC), and we look forward to sharing these updates at this year's San Antonio Breast Cancer Symposium,' said Dr. Takashi Owa, Chief Medicine Creation Officer and Chief Discovery Officer at Eisai Inc. 'We are particularly excited about our continued translational research to better understand how eribulin changes the microenvironment of cancer cells in patients living with MBC.'
This release discusses investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
About Metastatic Breast Cancer
Metastatic breast cancer is an advanced stage of the disease that occurs when cancer spreads beyond the breast to other parts of the body. In 2019 an estimated 268,600 women will be diagnosed with breast cancer in the United States and an estimated 41,760 women will die from the disease.1 It is estimated that approximately 6 to 10 percent of women with breast cancer will have metastatic disease at the time of diagnosis.2 Women diagnosed with metastatic disease have an estimated 5-year relative survival rate of about 27%.1
About HALAVEN (eribulin mesylate) Injection
HALAVEN (eribulin mesylate) is a microtubule dynamics inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
Discovered and developed by Eisai, eribulin is a synthetic analog of halichondrin B, a natural product that was isolated from the marine sponge Halichondria okadai. First in the halichondrin class, eribulin is a microtubule dynamics inhibitor. Eribulin is believed to work primarily via a tubulin-based mechanism that causes prolonged and irreversible mitotic blockage, ultimately leading to apoptotic cell death. Additionally, in preclinical studies of human breast cancer, eribulin demonstrated complex effects on the tumor biology of surviving cancer cells, including increases in vascular perfusion resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype, promoting the epithelial phenotype, opposing the mesenchymal phenotype. Eribulin has also been shown to decrease the migration and invasiveness of human breast cancer cells.
About Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania and our global demand chain organization resides in Maryland and North Carolina.
Contact:
Michele Randazzo
Tel: (201) 746-2979
EISAI CO., LTD. 
